Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretogogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans

European Journal of Endocrinology

Volumn 146, Issue 3, 2002, Pages 311-318

  Maccario, Mauro ^a   Veldhuis, Johannes D ^a   Broglio, Fabio ^a   Di Vito, Lidia ^a   Arvat, Emanuela ^a   Deghenghi, Romano ^a   Ghigo, Ezio ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; HEXARELIN; HYDROCORTISONE; PROLACTIN; SOMATOMEDIN C; GROWTH PROMOTOR; HUMAN GROWTH HORMONE; OLIGOPEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; ENTROPY; FLUSHING; GROWTH HORMONE RELEASE; HALF LIFE TIME; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE RELEASE; HYPOPHYSIS FUNCTION; MALE; MODEL; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PULSATILE HORMONE RELEASE; SIDE EFFECT; STATISTICAL ANALYSIS; TIME; VOLUNTEER; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENOCORTICOTROPIC HORMONE; ADULT; ENTROPY; FEMALE; GROWTH SUBSTANCES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INJECTIONS, SUBCUTANEOUS; MALE; OLIGOPEPTIDES; PROLACTIN; RADIOIMMUNOASSAY;

EID: 0036201718     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Endocrine activities of ghrelin, a natural GH secretagogue, in humans: A comparison with hexarelin, a non-natural peptidyl GHS, and GH-releasing hormone
2. Neuroendocrine control of growth hormone secretion
3. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human
4. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
5. Endocrine and non-endocrine activities of growth hormone secretagogues in humans
6. Peptidomimetic regulation of growth hormone secretion
7. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans
8. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats
9. Orally active growth hormone secretagogues: State of the art and clinical perspectives
10. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging
11. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects
12. Impact of GHRP-2 infusion for 30-90 days in older men and women with decreased GH secretion
13. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion
14. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men
15. Tripartite neuro-endocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: Pulsatile, entropic, and nyctohemeral mechanisms
16. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans
17. Age-related variations in the growth hormone response to growth hormone secretagogues
18. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults - A clinical research center study
19. Short-term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging
20. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects
21. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
22. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-1 secretion in healthy young men
23. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus
24. On the actions of the growth hormone-releasing hexapeptide, GHRP
25. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture
26. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats
27. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats
28. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: Partial response attenuation
29. Neurotransmitter control of growth hormone secretion in humans
30. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging
31. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles
32. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men (see comments)
33. Non-parametric deconvolution provides an objective assessment of GH responsiveness to GH-releasing stimuli in normal subjects
34. Quantification of hormone pulsatility via an approximate entropy algorithm
35. Orderliness of hormone release patterns: A complementary measure to conventional pulsatile and circadian analyses
36. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations
37. The orderliness of the growth hormone (GH) release process and the mean mass of GH secreted per burst are highly conserved in individual men on successive days
38. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in post-menopausal women
39. Operating behavior of dual or multiple endocrine pulse generators
40. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men
41. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females - A general clinical research center-based study
42. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamosomatotrope (growth hormone)-insulin-like growth factor I axis in the human: Evidence from pathophysiology and sex-steroid hormone replacement
43. Females secrete growth hormone with more process irregularity than males in both humans and rats
44. Growth hormone status during long-term hexarelin therapy
45. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin
46. Growth hormone secretagogues as corticotrophin-releasing factors
47. Atypical growth hormone releasing peptides